Alpha Compute (ALP) Q4 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2026 earnings summary
16 Jul, 2026Executive summary
Transitioned from biotech and digital asset treasury to vertically integrated AI infrastructure, focusing on confidential GPU-as-a-Service for enterprise, government, and consumer clients.
Secured $71 million in initial financing, completed rebrand, and acquired GAMEE, adding 120 million users to the ecosystem.
Signed first enterprise contract: a two-year, $32.2 million agreement for ALPHA-01 cluster, with $16.1 million annual contracted revenue and $7.5 million upfront payment received.
ALPHA-01 cluster is live; ALPHA-02 (576 NVIDIA B300 GPUs) under construction in Sweden, targeted for Q3 2026 deployment.
Qualified pipeline exceeds $200 million in annual revenue, with additional clusters (ALPHA-03, ALPHA-04) in progress.
Financial highlights
Fiscal year ended March 31, 2026: net loss of $38.6 million, up from $6.8 million prior year, driven by transition costs and one-time charges.
Cash and cash equivalents at fiscal year-end: $700,000; current liabilities: $13 million.
Subsequent events (as of July 13, 2026): cash increased to $10.3 million, reflecting contract payments, GAMEE acquisition, and share sales.
None of the $16.1 million contracted revenue or GAMEE revenue reflected in FY26 results; current annualized revenue run-rate estimated at $21–$23 million.
Outlook and guidance
Expecting significant revenue growth in current fiscal year as contracted revenue and GAMEE acquisition are recognized.
ALPHA-02 cluster to go live in Q3 2026; additional enterprise contracts and clusters expected to drive further growth.
Management aims to strengthen balance sheet and pursue full vertical integration, including real estate and energy assets.
Plans to increase reporting frequency, potentially moving to quarterly or monthly updates.
Latest events from Alpha Compute
- Shifted to TON-focused digital assets, raising $36.2M but facing liquidity and going concern risks.ALP
Q2 202618 Mar 2026 - Shelf registration targets $420.7M for TON token treasury and biotech R&D, with high risk factors.ALP
Registration Filing16 Dec 2025 - Up to $40M in securities offered to support R&D, operations, and strategic options amid financial pressures.ALP
Registration Filing16 Dec 2025 - Seeking $40M shelf offering to fund R&D and operations amid financial and Nasdaq compliance pressures.ALP
Registration Filing16 Dec 2025 - Major capital shift to TON token, 7.47M shares registered for resale, high dilution risk.ALP
Registration Filing16 Dec 2025 - Up to 189,719 shares are offered for resale as the company pivots to a TON token-focused strategy.ALP
Registration Filing16 Dec 2025 - Flexible securities offerings with digital asset options and strong governance protections.ALP
Registration Filing16 Dec 2025 - Net loss dropped sharply year-over-year as non-cash charges and operating expenses declined.ALP
Q4 202525 Jul 2025 - Net loss narrowed and costs fell as Portage Biotech explores strategic options amid trial pauses.ALP
Q2 202513 Jun 2025